

琉球大学学術リポジトリ

Effectiveness of Surveillance by Echocardiography for Cancer Therapeutics-Related Cardiac Dysfunction of Patients with Breast Cancer

メタデータ	言語: English 出版者: Elsevier 公開日: 2024-12-01 キーワード (Ja): キーワード (En): Heart failure, Cardio oncology, Cardiotoxic drugs, Echocardiography surveillance 作成者: Okushi, Yuichiro, Saijo, Yoshihito, Yamada, Hirotsugu, Toba, Hiroaki, Zheng, Robert, Seno, Hiromitsu, Takahashi, Tomonori, Ise, Takayuki, Yamaguchi, Koji, Yagi, Shusuke, Soeki, Takeshi, Wakatsuki, Tetsuzo, Sata, Masataka, Kusunose, Kenya メールアドレス: 所属:
URL	http://hdl.handle.net/20.500.12000/0002020587

1
2
3
4
5
6
7 **Effectiveness of Surveillance by Echocardiography for Cancer Therapeutics-Related**
8 **Cardiac Dysfunction of Patients with Breast Cancer**
9

10
11
12 Yuichiro Okushi (MD, PhD)^a, Yoshihito Saijo (MD, PhD)^b, Hirotugu Yamada (MD, PhD, FJCC)^c,
13 Hiroaki Toba (MD, PhD)^d, Robert Zheng (MD)^b, Hiromitsu Seno (MD)^b, Tomonori Takahashi (MD)^b,
14 Takayuki Ise (MD, PhD, FJCC)^b, Koji Yamaguchi (MD, PhD)^b, Shusuke Yagi (MD, PhD, FJCC)^b,
15 Takeshi Soeki (MD, PhD, FJCC)^b, Tetsuzo Wakatsuki (MD, PhD)^b, Masataka Sata (MD, PhD, FJCC)^b
16 Kenya Kusunose (MD, PhD)^{e,*}
17
18
19
20
21
22

23 ^aDepartment of Cardiovascular Medicine, Tokushima Naruto Hospital, Naruto, Japan

24 ^bDepartment of Cardiovascular Medicine, Tokushima University Hospital, Tokushima, Japan

25 ^cDepartment of Community Medicine for Cardiology, Tokushima University Graduate School of
26 Biomedical Sciences, Tokushima, Japan
27

28 ^dDepartment of Thoracic, Endocrine Surgery and Oncology, Tokushima University Graduate School of
29 Biomedical Science, Tokushima, Japan
30

31 ^eDepartment of Cardiovascular Medicine, Nephrology, and Neurology, Graduate School of Medicine,
32 University of the Ryukyus, Okinawa, Japan
33
34
35
36
37

38 ***Corresponding author:**

39 Kenya Kusunose, MD, PhD

40 Department of Cardiovascular Medicine, Nephrology, and Neurology, Graduate School of Medicine,
41 University of the Ryukyus, 207 Uehara, Nishihara Town, Okinawa, Japan

42 TEL: 81- 98-895-1150, FAX: 81- 98-895-1416

43 E-mail: echo.cardio@gmail.com

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Twitter : @Ken_Cardiology

ABSTRACT

Background: Cancer therapeutics-related cardiac dysfunction (CTRCD) affect the prognosis of patients with breast cancer. Echocardiographic surveillance of patients treated with anti-human epidermal growth factor receptor type 2 (HER2) antibodies has been recommended, but few reports have provided evidence on patients with breast cancer only. We aimed to evaluate the effectiveness of echocardiographic surveillance for breast cancer patients.

Methods: We identified 250 patients with breast cancer who were treated with anti-HER2 antibodies from July 2007 to September 2021. We divided 48 patients with echocardiographic surveillance every 3 months into the surveillance group and 202 patients without echocardiographic surveillance into the non-surveillance group. In the surveillance group, patients with a considerable reduction in global longitudinal strain of 15% were considered for the initiation of cardioprotective drugs. The composite outcome of CTRCD and acute heart failure was the study endpoint.

Results: The mean age was 59 ± 12 years. During the follow-up period of 15 months (12-17 months), 12 patients reached the endpoint. The surveillance group had significantly lower incidence of the composite outcome (2.1% vs. 5.5%, adjusted odds ratio: 0.28, 95% confidential intervals: 0.09–0.94; $p=0.039$) and higher rates of prescriptions of cardioprotective drugs than the non-surveillance group.

1
2
3
4
5
6
7 **Conclusions:** The incidence of cardiac complications was significantly lower in the
8
9 surveillance group than the non-surveillance group, which supports the effectiveness of
10
11 echocardiographic surveillance in patients with breast cancer.
12
13

14
15 **Key Words:** Heart failure; Cardio oncology; Cardiotoxic drugs; Echocardiography
16
17 surveillance
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

The prognosis of cancer patients has improved owing to advances in the early detection and treatment of cardiotoxicity caused by anticancer drugs. However, the major cardiotoxic effects of anticancer drugs have been reported more frequently [1, 2].

Anthracyclines and anti-human epidermal growth factor receptor type 2 (HER2) antibody, which is commonly used in the treatment of breast cancer patients, often cause cancer therapeutics-related cardiac dysfunction (CTRCD) and heart failure [3-5]. Among cancers, breast cancer develops at a relatively young age and complications of CTRCD and heart failure strongly affect the patient's prognosis and quality of life [6, 7].

Echocardiographic surveillance is recommended by the American Society of Echocardiography and the European Society of Cardiology with the initiation of these anticancer drugs [8, 9]. The diagnosis of cardiotoxicity has long been based on echocardiographic measurements of the left ventricular ejection fraction (LVEF). Global longitudinal strain (GLS) is a technique of echocardiography for the measurement of global long-axis function by myocardial strain and is a more sensitive and reproducible marker for detecting potential myocardial damage than LVEF [10]. Therefore, guidelines recommend follow-up echocardiographic examination using LVEF and GLS, every three months, to detect myocardial damage [8, 9, 11]. The SUCCOUR trial is the only prospective randomized controlled trial on CTRCD and GLS-guided cardio-protection [12-14]. These studies reported that the incidence of CTRCD was significantly lower for GLS-guided than for EF-guided follow up, although the change in LVEF was comparable between GLS-guided and EF-guided. However, these studies included diseases other than breast cancers

1
2
3
4
5
6
7 and the association with the incidence of heart failure was unclear. We hypothesized that
8
9 echocardiographic surveillance could better prevent the development of CTRCD and heart
10
11 failure, even in patients with breast cancer. This study aimed to assess the impact of
12
13 periodic echocardiographic surveillance in breast cancer therapy utilizing chemotherapy
14
15 with cardiotoxicity.
16
17

18 19 **Methods**

20 21 *Study population.*

22
23 This is a retrospective cohort study using data of Tokushima University Hospital. We
24
25 enrolled 264 patients with breast cancer who were treated with anti-HER2 antibody,
26
27 including in combination with anthracyclines, for the first time from July 2007 to
28
29 September 2021 at Tokushima University Hospital (**Fig. 1**). Patients who had previously
30
31 used anthracyclines or anti-HER2 antibody were not enrolled. We excluded 4 patients who
32
33 were lost to follow-up and 10 patients who did not undergo baseline LVEF or GLS
34
35 measurements before chemotherapy. All patients in the surveillance group underwent at
36
37 least three echocardiographic examinations (baseline and two follow-up examinations).
38
39 This study followed the Declaration of Helsinki and was approved by the Institutional
40
41 Review Board of the Tokushima University Hospital (no. 3186-2), and written informed
42
43 consents were obtained from the patients. Neither patients nor the public were involved in
44
45 the design, conduct, reporting, or dissemination of our research.
46
47
48
49
50
51
52
53
54
55

56 57 *Echocardiography.*

58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 LVEF was calculated using biplane method of disks. We calculated the average GLS using
8
9 three apical views. All GLS measurements were performed using a commercially available
10
11 echocardiographic system (Vivid E9 and E95; GE Medical, Milwaukee, WI, USA) [15].
12
13

14 *Clinical Outcomes.*

15
16
17
18 The main outcome was the composite outcome of CTRCD with symptoms and acute heart
19
20 failure. Subclinical left ventricular dysfunction was evaluated as the secondary outcome.
21

22
23 The follow-up period was from the initiation to the end of chemotherapy or the incidence of
24
25 the outcome. Outcomes were evaluated until March 2022 or the end of the follow-up
26
27 period. CTRCD was diagnosed when LVEF fell more than 10% below the baseline and
28
29 below the lower limit of normal LVEF. We defined the lower limit of normal LVEF as
30
31 50%, which is similar to the Japanese Society of Echocardiography [10]. Subclinical left
32
33 ventricular dysfunction was defined as GLS decreased by more than 15% compared to
34
35 baseline after anticancer therapy [8, 9]. We defined acute heart failure as the presence of
36
37 either B-type natriuretic peptide levels greater than 200 pg/mL or evidence of congestion
38
39 on X-ray/echocardiography, with the need for diuretic therapy.
40
41
42
43
44

45 *Surveillance.*

46
47
48
49 **Figure 2** shows the surveillance flow chart. Patients who had echocardiographic
50
51 surveillance of LVEF and GLS at up to every three months after start of chemotherapy
52
53 were assigned to the surveillance group. Patients who had not undergone periodic
54
55 echocardiography were assigned to the non-surveillance group. Surveillance was continued
56
57 until the end of chemotherapy or the development of the composite outcome. Most patients
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 who started treatment after July 2018 were classified into the surveillance group, with the
8
9 exception of a few patients who were not referred for echocardiographic surveillance. With
10
11 the diagnosis of CTRCD or acute heart failure at follow up, the surveillance was
12
13 terminated, and patients were considered for discontinuation of chemotherapy and initiation
14
15 of cardioprotective drugs. When subclinical left ventricular dysfunction occurred, patients
16
17 were considered for the initiation of cardioprotective drugs or shortening the follow-up
18
19 period. **Figure 3** shows representative cases of the surveillance group treated with
20
21 cardioprotective drugs.
22
23
24
25
26

27 *Statistical analysis.*

28
29
30 Continuous variables are expressed as mean \pm standard deviation (SD) or median
31
32 (interquartile range; IQR), and categorical variables as proportion (%). Baseline
33
34 characteristics were compared between the 2 groups by using an unpaired Student's t-test
35
36 or Fisher exact test as appropriate. The prescription rates of drugs between the 2 groups was
37
38 compared by using an unpaired Student's t-test. The propensity score (PS) was estimated
39
40 using a logistic regression model, with surveillance as the dependent variable, and the
41
42 following five clinically relevant covariates: age, body mass index (BMI), stage of cancer,
43
44 treatment with anthracyclines, and radiation therapy. Stage of cancer was selected as a
45
46 covariate because of significant differences between the two groups, age and BMI as risk
47
48 factors for CTRCD and acute heart failure, and anthracyclines and radiation therapy as both
49
50 [8, 16-18]. We used inverse probability treatment weighting with a logistic regression
51
52 model adjusted for the follow-up period and estimated the odds ratio (OR) and 95%
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 confidence interval (CI) with surveillance for the incidence of the composite outcome. We
8
9 assigned patients in the surveillance group a weight of $1 \div PS$ and patients in the non-
10
11 surveillance group a weight of $1 \div (1-PS)$. All statistical tests were two-sided and p -values
12
13 less than 0.05 were considered statistically significant. Statistical analysis was performed
14
15 using JMP 14.0 (SAS Institute Inc., Cary, NC, USA).
16
17
18

19 **Results**

20 *Patient characteristics.*

21
22
23 Among all patients (n=250), 99.6% (n=249) were female (**Table 1**). The mean age was 59
24
25 \pm 12 years and the follow-up period 15 months (12-17 months). There were 48 and 202
26
27 patients in the surveillance and non-surveillance groups, respectively. Compared to the
28
29 non-surveillance group, the surveillance group had a significantly higher number of stage
30
31 1-2 cancer, a shorter follow-up period, more chemotherapy with anthracyclines, and less
32
33 radiation therapy. The distribution of age, sex, BMI, smoking, comorbidities, baseline
34
35 LVEF, cardioprotective drugs at baseline, and anthracycline equivalence dose was similar
36
37 between the two groups. Of all patients, 29.6% had hypertension. As antihypertensive
38
39 drugs, a total of 17.6% were taking angiotensin-converting enzyme inhibitors (ACEi) or
40
41 angiotensin receptor blockers (ARB), and 3.6% were using beta-blockers at baseline.
42
43
44
45
46
47
48
49

50 *Surveillance and cardioprotective drugs.*

The changes in left ventricular function in the surveillance group are shown in **Table 2**.

During the follow-up period of the surveillance, the median decline in LVEF from baseline was 4% and the median relative decline in GLS from baseline was 10.7%.

The prescription rates of cardioprotective drugs before and after chemotherapy are shown in **Table 3**. In the surveillance group, 19 (39.6%) patients developed subclinical left ventricular dysfunction. For these patients, ACEi, ARB, and beta-blockers were prescribed at the physician's discretion. The results showed that 11 (57.9%) were prescribed cardioprotective drugs; 6 patients (31.6%) were prescribed only ACEi, ARB, or beta-blockers and 5 patients (26.3%) were prescribed a two-drug combination. Some patients in the non-surveillance group were also prescribed these drugs for hypertension and palpitations. After chemotherapy, significantly more patients in the surveillance group were treated with cardioprotective drugs than in the non-surveillance group (34.0% vs. 18.9%, $p=0.024$), especially beta-blockers only (8.5% vs. 1.0%, $p=0.004$) and combination therapy (12.8% vs. 4.2%, $p=0.025$).

Outcomes.

The composite outcome occurred in 12 patients (4.8%) overall (**Table 4**). Their mean age was 61 years, six (50%) had cancer stage 1-2, six (50%) were treated with anthracycline, nine (75%) with radiation therapy, and the median time to outcomes onset was about 13 months. In the surveillance group, one patient had CTRCD with shortness of breath at the first follow-up 3 months after the start of chemotherapy. In the non-surveillance group, two patients developed CTRCD with shortness of breath, eight patients developed CTRCD with

1
2
3
4
5
6 acute heart failure, and one patient developed acute heart failure only. After adjusting for
7
8 inverse probability treatment weighting and follow-up period, the surveillance group had a
9
10 significantly lower incidence of the composite outcome than the non-surveillance group
11
12 (2.1% vs. 5.5%, OR:0.28, 95% CI:0.09–0.94; $p=0.039$). Of the 12 patients, 5 patients were
13
14 hospitalized for acute heart failure and 2 patients did not have EF improve to above 50%,
15
16 all in the non-surveillance group. Six patients were not restarted on chemotherapy, and they
17
18 were either discontinued due to the development of CTRCD or deemed ineligible for
19
20 further treatment.
21
22
23
24

25 26 27 **Discussion**

28
29
30 The main findings of this study were 1) the composite outcome of CTRCD and acute heart
31
32 failure was present in 4.8% of the patients with breast cancer receiving chemotherapy; 2)
33
34 The surveillance group had a lower composite outcome and a higher rate of prescriptions
35
36 for cardioprotective drugs than the non-surveillance group; 3) 39.6% of patients in the
37
38 surveillance group developed subclinical left ventricular dysfunction, and half of the
39
40 patients with subclinical left ventricular dysfunction were prescribed cardioprotective
41
42 drugs.
43
44
45
46
47

48 To the best of our knowledge, this study is the first to report that echocardiographic
49
50 surveillance reduces the composite outcome of cardiotoxicity in a study of breast cancer
51
52 patients only.
53
54
55

56 ***Impact of surveillance.*** This study showed that the surveillance group had a significantly
57
58 lower incidence of composite outcomes than the non-surveillance group. Early detection of
59
60

1
2
3
4
5
6
7 cardiac dysfunction by echocardiographic surveillance and initiation of cardioprotective
8
9 drugs prevent a decrease in LVEF [19, 20]. In addition, it has been reported that GLS-
10
11 guided initiation of cardioprotective drugs can reduce the progression of myocardial
12
13 dysfunction better than LVEF-guided initiation. This is because a decrease in GLS precedes
14
15 a decrease in LVEF [21, 22], and GLS-guidance allows for early onset of treatment of
16
17 cardiac dysfunction [13]. In this study, six patients who developed the composite outcome
18
19 were unable to resume chemotherapy, and two of them did not recover LVEF above 50%.
20
21 Since these factors affect prognosis, preventing heart failure and LVEF decline through
22
23 surveillance may improve long-term prognosis.
24
25
26
27

28
29
30 Nine of the eleven patients with the composite outcome in the non-surveillance group had
31
32 heart failure and were started on diuretic therapy, but one patient with the composite
33
34 outcome in the surveillance group had no congestion and did not require diuretics.
35

36
37 Surveillance leads to early detection and treatment of CTRCD before symptoms of heart
38
39 failure appear, which promotes recovery of LVEF and reduces cardiac events [19]. One
40
41 patient developed CTRCD three months after the initiation of trastuzumab therapy. Cardiac
42
43 damage has been reported to occur early after the initiation of trastuzumab treatment [23].
44

45
46 In addition to the surveillance protocol of the guidelines, we shortened the follow-up period
47
48 interval for patients at high risk for CTRCD and those with reduced GLS. Adjusting the
49
50 follow-up period to suit individual patients may further reduce the incidence of CTRCD.
51
52

53
54 ***Cardioprotective drugs.*** Patients with cardiac damage due to chemotherapy are likely to
55
56 benefit from ACEi or ARB and beta-blocker treatment [24]. Combination therapy may be
57
58
59
60
61

1
2
3
4
5
6
7 more effective than either therapy alone [4, 19]. However, the initiation rate of
8
9 cardioprotective agents was low in our study. This could be due to two reasons: The risk of
10
11 CTRCD after chemotherapy is lower than that during chemotherapy; this is demonstrated in
12
13 the case of the patient who developed subclinical left ventricular dysfunction at the end of
14
15 chemotherapy. Second, overall, breast cancer patients tend to be younger than patients with
16
17 other types of cancer and have lower blood pressures and pulse rates. ACEi and ARB tend
18
19 to lower blood pressure, and beta-blockers tend to lower the pulse rate. Therefore,
20
21 cardioprotective agents should be tailored to individual patients.
22
23
24

25
26
27 Prophylactic administration of cardioprotective drugs at the initiation of anticancer therapy
28
29 may be beneficial for reducing the incidence of CTRCD. However, the reported incidence
30
31 of CTRCD is not high in patients with breast cancer, and it is necessary to identify patients
32
33 who would benefit from prophylactic administration in terms of health care economics and
34
35 complications.
36
37
38

39
40 ***Perspectives.*** Although the cardio-oncology field has evolved, the importance of CTRCD
41
42 surveillance is still poorly recognized. In many institutions, chemotherapy for breast cancer
43
44 patients is administered by breast surgeons or oncologists, not cardiologists, and systems
45
46 and protocols have not yet been established for CTRCD surveillance. Close collaboration
47
48 between cardiologists and managing physicians may promote echocardiographic
49
50 surveillance, which may improve prognosis and maintain the quality of life of patients with
51
52 breast cancer. We believe that this study will support the effectiveness of surveillance and
53
54 raise awareness regarding its necessity. Further research is needed on the effectiveness of
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 tailoring surveillance and prophylactic cardioprotective therapy according to individual
8
9 cardiovascular risk.

10
11
12 **Limitations.** First, the potential differences between the two groups were adjusted using
13
14 inverse probability treatment weighting but never completely. The number of covariates
15
16 was limited because of the small number of incidence of outcomes. Therefore, it was not
17
18 possible to adjust for all risk factors for CTRCD and acute heart failure. This
19
20 nonrandomized observational prospective study could also be affected by hidden bias due
21
22 to unknown unadjusted differences. The non-surveillance group included one male patient
23
24 and tended to have a higher stage of cancer. The hidden biases may have remained in these
25
26 patients. Second, this was a single-center retrospective study, and may have been biased.
27
28 Third, cardioprotective drugs for subclinical left ventricular dysfunction were administered
29
30 at the cardiologist's discretion. Fourth, the incidence of CTRCD in the surveillance group
31
32 in this study was lower than those reported in other studies. Fifth, in the non-surveillance
33
34 group, the incidence of subclinical left ventricular dysfunction could not be assessed
35
36 accurately because echocardiography was performed irregularly and only at the physician's
37
38 discretion. Therefore, it was not possible to compare the incidence of subclinical left
39
40 ventricular dysfunction between the two groups. Sixth, since this study included long-term
41
42 patients from 2007 to 2019, there may have been differences in anticancer treatment
43
44 protocols and in pharmacological and surgical therapies between patients.
45
46
47
48
49
50
51
52

53
54
55 **Conclusions**
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 The incidence of the composite outcome of CTRCD with a symptom and acute heart failure
8
9 was significantly lower in the surveillance group than in the non-surveillance group.

10
11 According to new guidelines, it was mentioned that early detection of CTRCD allows
12
13 clinicians to incorporate cardioprotective therapy before LVEF is significantly reduced, and
14
15 also decreases the risk of interruption of cancer treatment affecting patient survival [25].
16
17

18
19 This study supports the effectiveness of echocardiographic surveillance and that statement
20
21 of new guideline.
22
23

24
25
26
27
28 **Acknowledgments:** We gratefully acknowledge the work of past and present members of
29
30 the Ultrasound Examination Center of Tokushima University Hospital. We would like to
31
32 thank Editage (www.editage.com) for English language editing.
33
34

35
36 **Conflicts of Interest:** None
37
38

39
40 **Contributors:** H Yamada conceived the idea for this study. Y Okushi conducted data
41
42 analyses. The initial draft of the manuscript was produced by K Kusunose and Y Okushi.
43
44 All the authors were involved in interpreting the results and writing the manuscript. All
45
46 authors have read and approved the final manuscript.
47
48

49
50 **Funding:** This work was partially supported by JSPS Kakenhi Grants (Number 20K17084
51
52 to Y. Okushi, 19H03654 to M. Sata, and 23K07509 to K. Kusunose).
53
54
55
56
57
58
59
60
61

References

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. *CA Cancer J Clin* 2012;62:220-41.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. *Eur J Cancer* 2013;49:1374-403.
3. Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. *Nat Rev Cardiol* 2015;12:547-58.
4. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation* 2015;131:1981-8.
5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. *N Engl J Med* 2001;344:783-92.
6. Katanoda K, Shibata A, Matsuda T, Hori M, Nakata K, Narita Y, et al. Childhood, adolescent and young adult cancer incidence in Japan in 2009-2011. *Jpn J Clin Oncol* 2017;47:762-71.
7. Partridge AH, Hughes ME, Warner ET, Ottesen RA, Wong YN, Edge SB, et al. Subtype-dependent relationship between young age at diagnosis and breast cancer survival. *J Clin Oncol* 2016;34:3308-14.
8. Zamorano JL, Lancellotti P, Rodriguez Munoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J* 2016;37:2768-801.
9. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2014;15:1063-93.
10. Oikonomou EK, Kokkinidis DG, Kampaktsis PN, Amir EA, Marwick TH, Gupta D, et al. Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis. *JAMA Cardiol* 2019;4:1007-18.
11. Onishi T, Fukuda Y, Miyazaki S, Yamada H, Tanaka H, Sakamoto J, et al. Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction. *J Echocardiogr* 2021;19:1-20.
12. Negishi T, Thavendiranathan P, Negishi K, Marwick TH, SUCCOUR investigators. Rationale and design of the strain surveillance of chemotherapy for improving cardiovascular outcomes: The SUCCOUR Trial. *JACC Cardiovasc Imaging* 2018;11:1098-105.

13. Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J, et al. Strain-guided management of potentially cardiotoxic cancer therapy. *J Am Coll Cardiol* 2021;77:392-401.
14. Negishi T, Thavendiranathan P, Penicka M, Lemieux J, Murbraech K, Miyazaki S, et al. Cardioprotection using strain-guided management of potentially cardiotoxic cancer therapy: 3-year results of the SUCCOUR Trial. *JACC Cardiovasc Imaging* 2023;16:269-78.
15. Daimon M, Akaishi M, Asanuma T, Hashimoto S, Izumi C, Iwanaga S, et al. Guideline from Japanese Society of Echocardiography: 2018 focused update incorporated into Guidance for the Management and Maintenance of Echocardiography Equipment. *J Echocardiogr* 2018;16:1-5.
16. Virizuela JA, Garcia AM, de Las Penas R, Santaballa A, Andres R, Beato C, et al. SEOM clinical guidelines on cardiovascular toxicity (2018). *Clin Transl Oncol* 2019;21:94-105.
17. Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2017;35:893-911.
18. Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio-oncology. *Mayo Clin Proc* 2014;89:1287-306.
19. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomo G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. *J Am Coll Cardiol* 2010;55:213-20.
20. Negishi K, Negishi T, Haluska BA, Hare JL, Plana JC, Marwick TH. Use of speckle strain to assess left ventricular responses to cardiotoxic chemotherapy and cardioprotection. *Eur Heart J Cardiovasc Imaging* 2014;15:324-31.
21. Saijo Y, Kusunose K, Yamada N, Yamada H, Nishio S, Hirata Y, et al. Sequential speckle tracking imaging to detect early stage of cancer therapeutics-related cardiac dysfunction in a patient with breast cancer. *J Echocardiogr* 2020;18:134-5.
22. Negishi K, Negishi T, Hare JL, Haluska BA, Plana JC, Marwick TH. Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. *J Am Soc Echocardiogr* 2013;26:493-8.
23. Emren SV, Tuluze SY, Levent F, Tuluze K, Kalkan T, Yildiz Y, et al. Evaluation of trastuzumab-induced early cardiac dysfunction using two-dimensional strain echocardiography. *Med Ultrason* 2015;17:496-502.
24. Copur MS, Obermiller A. An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition. *Clin Colorectal Cancer* 2011;10:151-6.
25. Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). *Eur Heart J Cardiovasc Imaging* 2022;23:e333-465.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7 **Figure Title**
8
9

10 **Figure 1 Flowchart of the study.** We enrolled 264 patients with breast cancer who
11 received anti-HER2 antibodies for the first time from July 2007 to September 2021 at
12 Tokushima University Hospital. After excluding patients who were lost to follow-up and
13 did not undergo baseline left ventricular ejection fraction or global longitudinal strain
14 measurement before chemotherapy, 250 patients were included. There were 48 patients in
15 the surveillance group and 202 patients in the non-surveillance group.
16
17
18
19
20
21
22
23

24
25 GLS, global longitudinal strain; HER2, human epidermal growth factor receptor type 2;
26
27 LVEF, left ventricular ejection fraction.
28
29
30

31 **Figure 2 Surveillance protocol of this study.** In the surveillance group, 48 patients
32 underwent follow-up echocardiographic examinations every one to three months after
33 baseline, and left ventricular ejection fraction and global longitudinal strain were measured
34 each time. When subclinical left ventricular dysfunction occurred, the patients were
35 considered for initiation of cardioprotective drugs or shortening of the follow-up period.
36
37
38
39
40
41
42
43

44 AHF, acute heart failure; CTRCD, cancer therapeutics-related cardiac dysfunction;
45
46 GLS, global longitudinal strain; LVEF, left ventricular ejection fraction.
47
48
49
50
51
52

53 **Figure 3 Representative cases of the surveillance group with cardioprotective drugs.**
54

55
56 The global longitudinal strain (GLS) bull's-eye diagram, follow-up echocardiographic
57 measurements, and cardioprotective drugs from baseline to the sixth follow-up. Red letters
58
59
60
61

1
2
3
4
5
6
7 are used when GLS was lower than normal (-16% to -19%) or when Δ GLS was higher
8
9 Δ 15%.

10
11
12 LVEF, left ventricular ejection fraction.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1 Baseline characteristics with and without surveillance.

	All Patients (n=250)	Surveillance (n=48)	Non- Surveillance (n=202)	<i>p</i>
Follow-up period (months)	15 (12-17)	13 (8-16)	15 (13-18)	0.005
Age (years)	59±12	57±12	60±12	0.141
Female (%)	99.6	100.0	99.5	0.625
BMI	23.3±4.5	23.5±4.8	23.3±4.6	0.962
Stage 1-2 (%)	68.4	91.7	62.9	<0.001
Smoking (%)	15.2	16.7	14.9	0.753
Hypertension (%)	29.6	27.1	30.2	0.671
Diabetes mellitus (%)	7.2	2.1	8.4	0.127
Hyperlipidaemia (%)	11.2	12.5	10.9	0.751
Chronic heart failure (%)	0.8	0.0	1.0	0.489
Myocardial infarction (%)	0.8	0.0	1.0	0.489
Baseline LVEF (%)	65.1±4.0	65.1±3.2	65.1±4.1	0.992
Pre ACEi/ARB (%)	17.6	18.8	17.3	0.816
Pre Beta blocker (%)	3.6	6.3	3.0	0.273
Anthracycline (%)	52.4	68.8	48.5	0.015
Anthracycline equivalence dose (mg/m ²)	190±47	197±39	188±49	0.303
Radiation (%)	46.8	33.3	50.0	0.038

Data are presented as percentage of patients or median (interquartile range).

BMI, body mass index; LVEF, left ventricular ejection fraction; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

Table 2 The changes in left ventricular function in the surveillance group.

	Baseline (%)	Post (%)	Δ LVEF (%)	$\Delta\%$ GLS (%)
LVEF	65 \pm 3	60 \pm 4	4 (1-7)	
GLS	-19.9 \pm 2.5	-17.6 \pm 2.5		10.7 (0.0-20.6)

Data of the incidence of outcomes are presented as number (proportion).

LVEF, left ventricular ejection fraction; GLS, global longitudinal strain.

Table 3 The prescription rates of drugs before and after chemotherapy.

Treatment	<i>Before chemotherapy</i>			<i>After chemotherapy</i>		
	<u>Surveillance</u> (n=48)	<u>Non-surveillance</u> (n=202)	<i>p</i>	<u>Surveillance</u> (n=47)	<u>Non-surveillance</u> (n=191)	<i>p</i>
All (%)	10 (20.8)	36 (17.8)	0.628	16 (34.0)	36 (18.9)	0.024
Only ACEi/ARB (%)	7 (14.6)	30 (14.9)	0.963	6 (12.8)	26 (13.6)	0.879
Only Beta blocker (%)	1 (2.1)	1 (0.5)	0.267	4 (8.5)	2 (1.0)	0.004
Combination (%)	2 (4.2)	5 (2.5)	0.523	6 (12.8)	8 (4.2)	0.025

ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker.

Table 4 The incidence and odds ratio of the composite outcome.

	All Patients (n=250)	Surveillance (n=48)	Non- Surveillance (n=202)	*Adjusted OR (95% CI)	<i>p</i>
Composite Outcome (%)	12 (4.8)	1 (2.1)	11 (5.5)	0.28 (0.09-0.94)	0.039

Data are presented as number (proportion).

OR, odds ratio; CI, confidence interval.

* OR was adjusted for inverse probability treatment weighting and follow-up period.